Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women.
Oliver PohlLine MarchandJean-Pierre GottelandSimon CoatesJörg TäubelUlrike LorchPublished in: British journal of clinical pharmacology (2018)
Administration of OBE022 was safe and had favourable pharmacokinetic characteristics and no clinically relevant interaction with food. Our results allow further investigation of OBE022 in preterm labour patients.
Keyphrases
- postmenopausal women
- bone mineral density
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- study protocol
- low birth weight
- randomized controlled trial
- preterm infants
- induced pluripotent stem cells
- risk assessment
- patient reported outcomes
- human health
- double blind